Targeting of MCL-1 in breast cancer-associated fibroblasts reverses their myofibroblastic phenotype and pro-invasive properties.

MLA

Bonneaud, Thomas L., et al. “Targeting of MCL-1 in Breast Cancer-Associated Fibroblasts Reverses Their Myofibroblastic Phenotype and pro-Invasive Properties.” Cell Death & Disease, vol. 13, no. 9, Sept. 2022, p. 787. EBSCOhost, https://doi.org/10.1038/s41419-022-05214-9.

APA

Bonneaud, T. L., Lefebvre, C. C., Nocquet, L., Basseville, A., Roul, J., Weber, H., Campone, M., Juin, P. P., & Souazé, F. (2022). Targeting of MCL-1 in breast cancer-associated fibroblasts reverses their myofibroblastic phenotype and pro-invasive properties. Cell Death & Disease, 13(9), 787. https://doi.org/10.1038/s41419-022-05214-9

Chicago

Bonneaud, Thomas L, Chloé C Lefebvre, Lisa Nocquet, Agnes Basseville, Julie Roul, Hugo Weber, Mario Campone, Philippe P Juin, and Frédérique Souazé. 2022. “Targeting of MCL-1 in Breast Cancer-Associated Fibroblasts Reverses Their Myofibroblastic Phenotype and pro-Invasive Properties.” Cell Death & Disease 13 (9): 787. doi:10.1038/s41419-022-05214-9.